Physician profile
James R Pera
NPI 1851335053
$7,036.90
in general payments reported to CMS, 2019-2025
30 companies · $922 in 2025
The $922 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $591 · 2021: $983 · 2022: $1,008 · 2023: $1,413 · 2024: $1,166 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,496 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,496.00 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $988.10 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Supernus Pharmaceuticals, INC. | $951.60 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $942.09 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $686.02 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $373.03 | 2019-2025 | |
| Adlon Therapeutics L.P. | $350.38 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $343.50 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Neos Therapeutics, LP | $318.28 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Sanofi Pasteur INC. | $238.23 | 2021-2025 | |
| Glaxosmithkline, LLC. | $224.13 | 2019-2023 | Bexsero |
| Kaleo, INC. | $208.64 | 2019-2024 | Auvi-Q |
| Cranial Technologies, INC | $182.12 | 2019-2025 | Doc Band |
| Collegium Pharmaceutical, INC. | $168.22 | 2025 | Jornay Pm |
| Sobi, INC | $141.74 | 2019-2024 | |
| Seqirus USA INC | $123.34 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $111.39 | 2025 | Neffy |
| Genentech USA, INC. | $97.39 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.39 | 2020-2021 | |
| Dermira, INC. | $78.80 | 2019-2021 | |
| Shire North American Group INC | $72.81 | 2019 | |
| Vertical Pharmaceuticals, LLC | $59.08 | 2019-2025 | Relexxii |
| Phadia US INC. | $49.74 | 2023-2024 | Immunocap |
| Kowa Pharmaceuticals America, INC. | $46.56 | 2025 | Zoryve |
| Astrazeneca Pharmaceuticals LP | $46.10 | 2024 | Flumist Quadrivalent |
| Smith+Nephew, INC. | $36.02 | 2019 | |
| Kyowa Kirin, INC. | $24.97 | 2023 | Crysvita |
| Verrica Pharmaceuticals INC. | $24.40 | 2024 | Ycanth |
| Noven Therapeutics, LLC | $22.26 | 2024 | Xelstrym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.77 | 2019 | |
| Abbvie INC. | $15.80 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Pera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.